Skip to content
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-PID – AAV-NAbs Positive Patients
    • VTX–806 – Cerebrotendinous Xanthomatosis
    • VTX-802 & VTX-803 – PFIC
    • VTX-801 – Wilson’s disease
    • VTX-801 – GATEWAY Clinical Trial
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-PID – AAV-NAbs Positive Patients
    • VTX–806 – Cerebrotendinous Xanthomatosis
    • VTX-802 & VTX-803 – PFIC
    • VTX-801 – Wilson’s disease
    • VTX-801 – GATEWAY Clinical Trial
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Category: Events

VIVET WILL BE AT THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Jean-Philippe Combal, Vivet Therapeutics’ CEO

Vivet presenting at 2018 Evercore ISI HEALTHCONx in Boston

Vivet Therapeutics CEO, Jean-Philippe Combal

VIVET ATTENDING JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE

Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2018 London Healthcare Conference on…

VIVET PRESENTING DURING 2018 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON

Anne Douar, Chief Development Officer of Vivet Therapeutics

VIVET THERAPEUTICS ATTENDING 2018 ESGCT 26TH ANNUAL CONGRESS IN LAUSANNE

Vivet Therapeutics will be at the upcoming European Society of Gene And Cell Therapy (ESGCT) 26th annual congress in Lausanne…

Vivet Presenting at 2018 Chardan Gene Therapy conference in New York

Vivet Therapeutics CEO, Jean-Philippe Combal, will be presenting and hosting 1×1 meetings during Chardan Gene Therapy conference in New York on October…

Vivet attending FierceBiotech 3rd Drug Development Forum in Boston

Vivet Therapeutics’ CEO, Jean-Philippe Combal

VIVET ANNOUNCES PRESENTATIONS ON ITS LEAD PRODUCT VTX-801 AT THE 2018 COPPER MEETING

Vivet Therapeutics announces different presentations

VIVET ATTENDING WEDBUSH PACGROW 2018 HEALTHCARE CONFERENCE IN NEW YORK

Vivet Therapeutics’ CEO, Jean-Philippe Combal

Vivet attending BIO 2018 in Boston on June 4-7

Vivet’s CEO, Jean-Philippe Combal and Thomas Daniel, BD Director, will be hosting 1×1 meetings during BIO 2018 in Boston on June 4-7.

← Previous
Next →
Twitter Linkedin
About us
  • Our DNA
  • Board members
  • Our team
  • Partners
  • Our DNA
  • Board members
  • Our team
  • Partners
Pipeline
  • VTX-PID – AAV-NAbs Positive Patients
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-802 & VTX-803 – PFIC
  • VTX-801 – Wilson’s disease
  • VTX-801 – GATEWAY Clinical Trial
  • VTX-PID – AAV-NAbs Positive Patients
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-802 & VTX-803 – PFIC
  • VTX-801 – Wilson’s disease
  • VTX-801 – GATEWAY Clinical Trial
Patients & Families
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact

Vivet Therapeutics Cookie Policy

Vivet Therapeutics Privacy Policy

Vivet Therapeutics
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}